Biotech

All Articles

Lykos will ask FDA to rethink its own choice following being rejected of MDMA therapy for post-traumatic stress disorder

.Complying with a poor showing for Lykos Rehabs' MDMA applicant for trauma at a latest FDA advising ...

AN 2 fifty percents roll call, ceases period 3 trial after data dissatisfy

.AN2 Therapies is reassessing its business in reaction to lackluster midphase information, swearing ...

Merck pays out $700M for bispecific, snooping autoimmune opening and odds to challenge Amgen in cancer

.Merck &amp Co. is actually paying out $700 thousand beforehand to challenge Amgen in a blood cancer...

Gilead pays out J&ampJ $320M to exit licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA decision for its own liver health condition medicine selad...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily observe the business putting together camping tents at basecamp responsi...

Entero laying off personnel, moving out of office and pausing R&ampD

.Mattress Liquidators has turned Entero Therapeutics white colored as a piece. The creditor bought E...

Exelixis falls ADC after deciding it's no suit for Tivdak

.Exelixis is actually losing hope on its own cells element (TF)- targeting antibody-drug conjugate a...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.Three full weeks after Roche's Genentech device ignored an SHP2 prevention contract, Relay Rehab ha...

Stoke's Dravet syndrome med launched of partial scientific grip

.Stoke Therapies' Dravet syndrome medication has been without a predisposed grip, getting rid of the...

Fierce Biotech's Gabrielle Masson offers Brutal 15 at NYSE

.Tough Biotech Associate Publisher Gabrielle Masson presented the 2024 class of Tough 15 winners on ...